Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia

Journal of Lipid Research

Volumn 37, Issue 11, 1996, Pages 2383-2393

  Parhofer, Klaus G ^a   Barrett, P Hugh R ^b   Demant, Thomas ^a   Richter, Werner O ^a   Schwandt, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

apheresis; apoB 100; kinetic models; lipoprotein metabolism; non steady sate kinetics

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LEUCINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; ARTICLE; CATABOLISM; CLINICAL ARTICLE; COMPARTMENT MODEL; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GAS CHROMATOGRAPHY; HETEROZYGOTE; HUMAN; IMMUNOADSORPTION; KINETICS; LIPOPROTEIN METABOLISM; MALE; MASS SPECTROMETRY; NEPHELOMETRY; PRIORITY JOURNAL; STEADY STATE; ULTRACENTRIFUGATION;

APOLIPOPROTEINS B; BLOOD COMPONENT REMOVAL; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE;

EID: 0030469866     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Stoffel, W., V. Greve, and H. Borberg. 1981. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet. 2: 1005-1007.
2. Seidel, D., V. W. Armstrong, and P. Schuff-Werner. 1991. The HELP LDL Apheresis Multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur. J. Clin. Invest. 21: 375-383.
3. Yokoyama, S. R., R. Hayashi, M. Satani, and A. Yamamoto. 1985. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 5: 613-622.
4. Richter, W. O., B. G. Jacob, M. M. Ritter, K. Suhler, K. Vierneisel, and P. Schwandt. 1993. 3-Year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein-B antibodies. Metabolism. 42: 888-894.
5. Tatami, R., N. Inoue, H. Itoh, B. Kishino, N. Koga, Y. Nakashima, T. Nishide, K. Okamura, Y. Saito, T. Teramoto, T. Yasugi, A. Yamamoto, and Y. Goto. 1992. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Arteriosclerosis. 95: 1-13.
6. Kroon, A. A., W. R. M. Aengavaeren. T. van der Werf, G. J. H. Uijen, J. H. C. Reiber, A. V. G. Bruschke, and A. F. H. Stalenhoef. 1996. LDL-apheresis atherosclerosis regression study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93: 1826-1835.
7. Borberg, H., and K. Oette. 1993. Experience with and conclusions from three different trials on low density lipoprotein apheresis. In Therapeutic Plasmapheresis (XII). T. Agishi, A. Kawamura, M. Mineshima, editors. VSP, Utrecht. 25-28.
8. Schuff-Werner, P., H. Gohlke, U. Bartmann, G. Baggio, M. C. Corti, A. Dinsenbacher, T. Eisenhauer, P. Grützmacher, C. Keller, U. Kettner, W. Kleophas, W. Köster, C. J. Olbrich, W. O. Richter, D. Seidel, and the HELP Study Group. 1994. The HELP apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. Eur. J. Clin. Invest. 24: 724-732.
9. Thompson, G. R., V. M. G. Maher, S. Matthews, Y. Kitano, G. Neuwirth, M. B. Shortt, G. Davies, A. Rees, A. Mir, R. J. Prescott, P. Defeyter, and A. Henderson. 1995. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345: 811-816.
10. Gaw, A., C. J. Packard, G. M. Lindsay, E. F. Murray, B. A. Griffin, M. J. Caslake, I. Colquhoun, D. J. Wheatley, A. R. Lorimer, and J. Shepard. 1996. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 16: 236-249.
11. Dixon, J. L., and H. N. Ginsberg. 1993. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 34: 167-179.
12. Sniderman, A. D., and K. Cianflone. 1993. Substrate delivery as a determinant of hepatic apoB secretion. Aterioscler. Thromb. 13: 629-636.
13. Thompson, G. R., R. P. Naoumova, and G. F. Watts. 1996. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37: 439-447.
14. Dixon, J. L., S. Furukawa, and H. N. Ginsberg. 1991. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem. 266: 5058-5086.
15. Kohen-Avramoglu, R., K. Cianflone, and A. D. Sniderman. 1995. The role of neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J. Lipid Res. 36: 2513-2528.
16. Cummings, M. H., G. F. Watts, C. Pal, M. Umpleby, T. R. Hennessy, R. Naoumova, and P. H. Sönksen. 1995. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin. Sci. 88: 225-233.
17. Cummings, M. H., G. F. Watts, A. M. Umpleby, T. R. Hennessy, R. Naoumova, B. M. Slavin, G. R. Thompson, and P. H. Sönksen. 1995. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 38: 959-967.
18. Watts, G. F., R. Naoumova, M. H. Cummings, M. Umpleby, B. M. Slavin, T., P. H. Sönksen, and G. R. Thompson. 1995. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects. Metabolism. 44: 1052-1057.
19. Pfohl, M., R. P. Naoumova, C. Klass, W. Knisel, B. Jakober, T. Risler, and G. R. Thompson. 1994. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35: 1946-1955.
20. Naoumova, R. P., M. Pfohl, A. Sussekov, C. Neuwirth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1995. Acute up-regulation of cholesterol synthesis by LDL-apheresis: evidence for a threshold effect. Circulation. 92: I-103 (abstract).
21. Arends, J., D. M. Bier, G. Schafer, V. W. Armstrong, J. Thiery, D. Seidel, and P. Schauder. 1993. No evidence for feedback inhibition of hepatic apolipoprotein-B (apoB) production after extracorporeal low density lipoprotein precipitation as determined by [1-C-13]leucine infusion in normal volunteers. Eur. J. Clin. Invest. 23: 602-614.
22. Soutar, A. K., N. B. Myant, and G. R. Thompson. 1979. Metabolism of apolipoprotein B-containing lipoproteins in familial hypercholesterolemia. Atherosclerosis. 32: 315-325.
23. Thompson, G. R., T. Spinks, A. Ranicar, and N. B. Myant. 1977. Non-steady-state studies of low-density lipoprotein turnover in familial hypercholesterolemia. Clin. Sci. Mol. Med. 52: 361-369.
24. Eriksson, M., L. Berglund, J. Gabrielsson, B. Lantz, and B. Angelin. 1993. Non-steady-state kinetics of low density lipoproteins in man - studies after plasma exchange in healthy subjects and patients with familial hypercholesterolemia. Eur. J. Clin. Invest. 23: 746-752.
25. Parhofer, K. G., P. H. R. Barrett, D. M. Bier, and G. Schonfeld. 1991. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J. Lipid Res. 32: 1311-1323.
26. Parhofer, K. G., P. H. R. Barrett, D. M. Bier, and G. Schonfeld. 1992. Lipoproteins containing the truncated apolipoprotein, apoB-89, are cleared from human plasma more rapidly than apoB-100-contain lipoproteins in vivo. J. Clin. Invest. 89: 1931-1937.
27. Klein, R. L., and D. B. Zilversmit. 1984. Direct determination of human and rabbit apolipoprotein B selectively precipitated with butanol-isopropyl ether. J. Lipid Res. 25: 1380-1386.
28. Demant, T., C. J. Packard, P. Steward, A. Bedynek, A. G. Calder, J. Shepherd, and D. Seidel. 1994. Sensitive mass spectrometry techniques for measuring metabolism of human apolipoprotein B in vivo. Clin. Chem. 40: 1825-1827.
29. Cobelli, C., G. Toffolo, and D. M. Foster. 1992. Tracer to tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 262: E968-E975.
30. Parhofer, K. G., P. H. R. Barrett, J. Dunn, and G. Schonfeld. 1993. Effect of pravastatin on metabolic parameters of apolipoprotein-B in patients with mixed hyperlipoproteinemia. Clin. Invest. 71: 939-946.
31. Beltz, W. F., Y. A. Kesaniemi, B. V. Howard, and S. M. Grundy. 1985. Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins. J. Clin. Invest. 76: 575-585.
32. Demant, T., C. J. Packard, H. Demmelmair, P. Stewart, A. Bedynek, D. Bedford, D. Seidel, and J. Shepard. 1996. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am. J. Physiol. 270: E1022-E1036.
33. Kesaniemi, Y. A., G. L. Vega, and S. M. Grundy. 1982. Kinetics of apolipoprotein B in normal and hyperlipidemic man: review of current data. In Lipoprotein Kinetics and Modeling. M. Berman, S. M. Grundy, and B. V. Howard, editors. Academic Press, New York. 181-205.
34. Phair, R. D., M. G. Hammond, J. A. Bowden, M. Fried, W. A. Fisher, and M. Berman. 1975. A preliminary model for human lipoprotein metabolism in hyperlipoproteinemia. Fed. Proc. 34: 2263-2270.
35. Cobelli, C., and J. DiStefano III. 1980. Parameter and structural identifiability concepts and ambiguities: a critical review and analysis. Am. J. Physiol. 239: R7-R24.
36. Foster, D. M., R. L. Aamodt, R. J. Henkin, and M. Berman. 1979. Zink metabolism in humans: a kinetic model. Am. J. Physiol. 237: R340-R349.
37. Vega, G. L., M. A. Denke, and S. M. Grundy. 1991. Metabolic basis of primary hypercholesterolemia. Circulation. 84: 118-128.
38. 3H]leucine tracer. J. Lipid Res. 32: 1823-1836.
39. Fisher, W. R., L. A. Zech, and P. W. Stacpoole. 1994. ApoB metabolism in familial hypercholesterolemia - inconsistencies with the LDL receptor paradigm. Arterioscler. Thromb. 14: 501-510.
40. Foster, D. M., A. Chait, J. J. Albers, R. A. Failor, C. Harris, and J. D. Brunzell. 1986. Evidence for kinetic heterogeneity among human low density lipoproteins. Metabolism. 35: 685-696.
41. Grundy, S. M., G. L. Vega, and D. W. Bilheimer. 1985. Effects of combined therapy with mevinolin and interruption of bile acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann. Intern. Med. 103: 339-343.
42. Sato, R., T. Imanaka, A. Takatsuki and T. Takano. 1990. Degradation of newly synthesized apolipoprotein B-100 in a pre-Golgi compartment. J. Biol. Chem. 265: 11880-11884.
43. Dashti, N. 1992. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells. J. Biol. Chem. 267: 7160-7169.
44. Craig, W. Y., R. Nutlik, and A. D. Cooper. 1988. Regulation of apoprotein synthesis and secretion in the human hepatoma HepG2: the effect of exogenous lipoprotein. J. Biol. Chem. 236: 13880-13890.
45. Bilheimer, D. W., S. M. Grundy, M. S. Brown, and J. L. Goldstein. 1983. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA. 80: 4124-4128.